Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCL
December 15th 2018Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.